BACKGROUND: In orthopedic field is growing interest in the use of stem cells: this mesenchymal multipotent line (MSCs) can lead to differentiation into osteocytes and thus the formation of bone tissue. In literature applications of this line are described in injuries of tendons and ligaments, small bony avulsions, nonunion fractures and cartilage defects. AIM: Utilize MSCs expanded in laboratory in case of atrophic pseudoarthrosis of the upper limb. MATERIALS AND METHODS: We obtain the amount of cell necessary for the implant by the collaboration with the UO Haematological Department. For the procedure we make a blood sample from the iliac crest bone marrow and a subsequent phase of selection and cultivation of mesenchymal line for 3 weeks, to get a sufficient amount of tissue to be used, which is presented at the time of surgery on a scaffold made by autologous plasma gel and CaCl(2). We reassessed our experience in 8 different types of upper limb fractures result in pseudarthrosis and delayed of consolidation: 4 women and 4 men, average 44 years old followed with a follow-up of 50.3 months. In all cases the site of non-union has been revitalized (by microfractures and drilling) and a synthesis was performed with a rigid plate. So we fill the bone gap with autologous bone and mesenchymal stem cells expanded in the laboratory. RESULTS: We have a radiographic healing in 8 cases and no adverse events were highlighted. CONCLUSIONS: Using this cells line we obtained encouraging but certainly not conclusive impressions, according to the limited number of cases and lack of adequate comparative studies. In tissue engineering are also certainly needed further investigations and developments.
BACKGROUND: In orthopedic field is growing interest in the use of stem cells: this mesenchymal multipotent line (MSCs) can lead to differentiation into osteocytes and thus the formation of bone tissue. In literature applications of this line are described in injuries of tendons and ligaments, small bony avulsions, nonunion fractures and cartilage defects. AIM: Utilize MSCs expanded in laboratory in case of atrophic pseudoarthrosis of the upper limb. MATERIALS AND METHODS: We obtain the amount of cell necessary for the implant by the collaboration with the UO Haematological Department. For the procedure we make a blood sample from the iliac crest bone marrow and a subsequent phase of selection and cultivation of mesenchymal line for 3 weeks, to get a sufficient amount of tissue to be used, which is presented at the time of surgery on a scaffold made by autologous plasma gel and CaCl(2). We reassessed our experience in 8 different types of upper limb fractures result in pseudarthrosis and delayed of consolidation: 4 women and 4 men, average 44 years old followed with a follow-up of 50.3 months. In all cases the site of non-union has been revitalized (by microfractures and drilling) and a synthesis was performed with a rigid plate. So we fill the bone gap with autologous bone and mesenchymal stem cells expanded in the laboratory. RESULTS: We have a radiographic healing in 8 cases and no adverse events were highlighted. CONCLUSIONS: Using this cells line we obtained encouraging but certainly not conclusive impressions, according to the limited number of cases and lack of adequate comparative studies. In tissue engineering are also certainly needed further investigations and developments.
Authors: Angelos Kaspiris; Argyris C Hadjimichael; Elias S Vasiliadis; Dionysios J Papachristou; Peter V Giannoudis; Elias C Panagiotopoulos Journal: J Clin Med Date: 2022-07-04 Impact factor: 4.964
Authors: Ralph S Marcucio; Aaron Nauth; Peter V Giannoudis; Chelsea Bahney; Nicolas S Piuzzi; George Muschler; Theodore Miclau Journal: J Orthop Trauma Date: 2015-12 Impact factor: 2.512
Authors: Ryan J Warth; Paul G Shupe; Xueqin Gao; Mohammad Syed; Walter R Lowe; Johnny Huard; Christopher D Harner Journal: Clin Orthop Relat Res Date: 2020-03 Impact factor: 4.755
Authors: Enrique Gómez-Barrena; Norma G Padilla-Eguiluz; Cristina Avendaño-Solá; Concepción Payares-Herrera; Ana Velasco-Iglesias; Ferran Torres; Philippe Rosset; Florian Gebhard; Nicola Baldini; Juan C Rubio-Suarez; Eduardo García-Rey; José Cordero-Ampuero; Javier Vaquero-Martin; Francisco Chana; Fernando Marco; Javier García-Coiradas; Pedro Caba-Dessoux; Pablo de la Cuadra; Philippe Hernigou; Charles-Henri Flouzat-Lachaniette; François Gouin; Didier Mainard; Jean Michel Laffosse; Miriam Kalbitz; Ingo Marzi; Norbert Südkamp; Ulrich Stöckle; Gabriela Ciapetti; Davide Maria Donati; Luigi Zagra; Ugo Pazzaglia; Guido Zarattini; Rodolfo Capanna; Fabio Catani Journal: Stem Cells Int Date: 2018-02-22 Impact factor: 5.443